'''Befiradol''' ('''F-13,640'''; '''NLX-112''') is a very [[potency (pharmacology)|potent]] and highly [[binding selectivity|selective]] [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] [[full agonist]]. A SAR study revealed that replacement of the dihalophenyl moiety by 3-[[benzothiophene|benzothienyl]] increases maximal [[Efficacy#Pharmacology|efficacy]] from 84% to 124% (Ki=2.7 nM).<ref>{{cite journal | doi = 10.1021/jm100835q | pmid = 20860381 | volume=53 | issue=19 | title=Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists |date=October 2010 | journal=J. Med. Chem. | pages=7167–79 | vauthors=Bollinger S, Hübner H, Heinemann FW, Meyer K, Gmeiner P}}</ref> In recombinant cell lines expressing human [[5-HT1A receptor]]s, befiradol exhibits high agonist efficacy for a variety of signal transduction read-outs, including [[Extracellular signal–regulated kinases|ERK]] phosphorylation, [[G protein|G-protein]] activation, [[Receptor-mediated endocytosis|receptor internalization]] and [[adenylyl cyclase]] inhibition.<ref name=":0">{{Cite journal|last=Newman-Tancredi|first=Adrian|last2=Martel|first2=Jean-Claude|last3=Cosi|first3=Cristina|last4=Heusler|first4=Peter|last5=Lestienne|first5=Fabrice|last6=Varney|first6=Mark A.|last7=Cussac|first7=Didier|date=2017-06-14|title=Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist|url=https://www.ncbi.nlm.nih.gov/pubmed/28612503|journal=The Journal of Pharmacy and Pharmacology|volume=69|issue=9|pages=1178–1190|doi=10.1111/jphp.12762|issn=2042-7158|pmid=28612503}}</ref> In rat hippocampal membranes it preferentially activates [[G alpha subunit|GalphaO proteins]].<ref name=":0" /> In neurochemical experiments, befiradol activated 5-HT1A autoreceptors in rat dorsal Raphe nucleus as well as 5-HT1A heteroreceptors on pyramidal neurons in the frontal cortex.<ref>{{Cite journal|last=Lladó-Pelfort|first=Laia|last2=Assié|first2=Marie-Bernadette|last3=Newman-Tancredi|first3=Adrian|last4=Artigas|first4=Francesc|last5=Celada|first5=Pau|date=May 2012|title=In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat|url=https://www.ncbi.nlm.nih.gov/pubmed/22147258|journal=Psychopharmacology|volume=221|issue=2|pages=261–272|doi=10.1007/s00213-011-2569-9|issn=1432-2072|pmid=22147258}}</ref> It has powerful [[analgesic]] and [[antiallodynic]] effects comparable to those of high doses of [[opioid]] [[painkiller]]s, but with fewer and less prominent [[adverse effect|side effect]]s, as well as little or no development of [[Drug tolerance|tolerance]] with repeated use.<ref name="pmid12595749">{{cite journal |vauthors=Bardin L, Tarayre JP, Malfetes N, Koek W, Colpaert FC |title=Profound, non-opioid analgesia produced by the high-efficacy 5-HT(1A) agonist F 13640 in the formalin model of tonic nociceptive pain |journal=Pharmacology |volume=67 |issue=4 |pages=182–94 |date=April 2003 |pmid=12595749 |doi=10.1159/000068404 |url=}}</ref><ref name="pmid12694810">{{cite journal |vauthors=Bruins Slot LA, Koek W, Tarayre JP, Colpaert FC |title=Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640 |journal=European Journal of Pharmacology |volume=466 |issue=3 |pages=271–9 |date=April 2003 |pmid=12694810 |doi= 10.1016/S0014-2999(03)01566-8|url=}}</ref><ref name="pmid15528450">{{cite journal |vauthors=Bardin L, Assié MB, Pélissou M, Royer-Urios I, Newman-Tancredi A, Ribet JP, Sautel F, Koek W, Colpaert FC |title=Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-<nowiki/>{[(5-methyl-pyridin-2-ylmethyl)-amino]-methyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=312 |issue=3 |pages=1034–42 |date=March 2005 |pmid=15528450 |doi=10.1124/jpet.104.077669 |url=}}</ref><ref name="pmid16254131">{{cite journal |vauthors=Colpaert FC, Deseure K, Stinus L, Adriaensen H |title=High-efficacy 5-hydroxytryptamine 1A receptor activation counteracts opioid hyperallodynia and affective conditioning |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=316 |issue=2 |pages=892–9 |date=February 2006 |pmid=16254131 |doi=10.1124/jpet.105.095109 |url=}}</ref><ref name="pmid17512927">{{cite journal |vauthors=Deseure K, Bréand S, Colpaert FC |title=Curative-like analgesia in a neuropathic pain model: parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist |journal=European Journal of Pharmacology |volume=568 |issue=1–3 |pages=134–41 |date=July 2007 |pmid=17512927 |doi=10.1016/j.ejphar.2007.04.022 |url=}}</ref>
